231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market
Lawyer and bioethicist Holly Fernandez Lynch joins us to explain a watershed test of the FDA's authority to revoke drug approvals. And STAT's Helen Branswell calls in to discuss the headline-grabbin...
20 Loka 202234min
230: BIO's messy transition, mRNA's future, & Biogen's next CEO
STAT Washington correspondent Rachel Cohrs joins us to explain the abrupt departure of the CEO of BIO, the lobbying group representing biotech on Capitol Hill, and its wider implications. We also disc...
13 Loka 202233min
229: Nobels for science, biotech dealmaking, & a friendly FTC
The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winning work in medicine and chemistry. We also discuss...
6 Loka 202228min
228: A surprise success in Alzheimer's and how FDA history seeded modern controversy
Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist ...
29 Syys 202235min
227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0
Heidi Tworek, a professor at the University of British Columbia and expert on public health communication, joins us to discuss President Biden's declaration that "the pandemic is over" and how leaders...
22 Syys 202234min
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellw...
15 Syys 202227min
225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treat...
8 Syys 202233min
224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
Our colleague Megan Molteni joins us to explain the scientific discoveries, rampant hype, and Silicon Valley billions behind the burgeoning field of longevity research. Then, we discuss the remarkable...
1 Syys 202234min
